From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: A systematic review and meta-analysis

Last Updated: Thursday, November 14, 2024

Researchers performed a literature review to compare the cost-effectiveness of three CDK4/6 inhibitors in the treatment of postmenopausal patients with advanced metastatic HR+ HER2- breast cancer. They found that none of the three evaluated CDK4/6 inhibitors were cost effective compared to treatment with letrozole/endocrine therapy alone. 

Current Medical Research and Opinion
Advertisement
News & Literature Highlights
Advertisement
Advertisement